Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.

Saved in:
Bibliographic Details
Title: Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Authors: Haderk F; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA., Chou YT; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA., Cech L; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA., Fernández-Méndez C; Instituto de Investigaciones Biomédicas 'Alberto Sols', Consejo Superior de Investigaciones Científícas (CSIC) y Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Yu J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, CA, USA.; Department of Urology, University of California, San Francisco, San Francisco, CA, USA., Olivas V; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA., Meraz IM; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Barbosa Rabago D; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA., Kerr DL; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Gomez C; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Allegakoen DV; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Guan J; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA., Shah KN; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA., Herrington KA; Center for Advanced Light Microscopy, University of California, San Francisco, San Francisco, CA, USA., Gbenedio OM; Department of Anatomy, University of California, San Francisco, San Francisco, CA, USA., Nanjo S; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan., Majidi M; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tamaki W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Pourmoghadam YK; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Rotow JK; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., McCoach CE; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Riess JW; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA., Gutkind JS; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA., Tang TT; Vivace Therapeutics, Inc., 1500 Fashion Island Blvd., Suite 102, San Mateo, CA, USA., Post L; Vivace Therapeutics, Inc., 1500 Fashion Island Blvd., Suite 102, San Mateo, CA, USA., Huang B; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.; Department of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, CA, USA.; Chan Zuckerberg Biohub, San Francisco, CA, USA., Santisteban P; Instituto de Investigaciones Biomédicas 'Alberto Sols', Consejo Superior de Investigaciones Científícas (CSIC) y Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Goodarzi H; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, CA, USA.; Department of Urology, University of California, San Francisco, San Francisco, CA, USA., Bandyopadhyay S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA., Kuo CJ; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA., Roose JP; Department of Anatomy, University of California, San Francisco, San Francisco, CA, USA., Wu W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Blakely CM; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Roth JA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bivona TG; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.
Source: Nature communications [Nat Commun] 2024 May 03; Vol. 15 (1), pp. 3741. Date of Electronic Publication: 2024 May 03.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-024-47423-0